1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Patient Preference: new trials by email Literature Review of Patient Preference trials Research Report on Patient Preference
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia Subcutaneous azacitidine, Oral decitabine/cedazuridine - Myelodysplastic Syndromes, Leukemia, Myeloid, Acute | Phase 3 | Active not recruiting | Otsuka Australia Pharmaceutical Pty Ltd | 13 | 2023-12-20 | 2025-03-20 |
Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic Syndromes (1)
Behavior (1) · Bone Marrow Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Health Behavior (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Leukemia (1) · Leukemia, Myeloid (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Patient Satisfaction (1)
decitabine and cedazuridine drug combination (1)
Otsuka Australia Pharmaceutical Pty Ltd (1)
Australia (1) · New Zealand (1)
Anoop Enjeti (1)